Decision Analysis of Post-Remission Therapy in Cytogenetically Intermediate-Risk AML
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Biology of Blood and Marrow Transplantation
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Decision Analysis of Post-Remission Therapy in Cytogenetically Intermediate-Risk AML: The Impact of FLT3-ITD, NPM1, and CEBPA
Biol. Blood Marrow Transplant 2016 Mar 31;[EPub Ahead of Print], S Kurosawa, H Yamaguchi, T Yamaguchi, K Fukunaga, S Yui, S Wakita, H Kanamori, K Usuki, N Uoshima, M Yanada, K Shono, T Ueki, I Mizuno, S Yano, J Takeuchi, J Kanda, H Okamura, Y Inamoto, K Inokuchi, T FukudaFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.